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OBJECTIVE: To estimate prevalence of Urinary Inconti-
nence (UI) in the Portuguese population. To determine the
costs of treatment (including incontinent pad usage) with
Tolterodine for patients suffering from chronic UI.
METHODS: Data from the National Health Survey per-
formed in 1995–96, involving a representative sample of
49718 people across mainland Portugal, was analyzed to
determine age, sex-specific and age-standardized preva-
lence rates of UI. The average consumption of pads by in-
continent patients was estimated from the information pro-
vided by the Centro Regional de Saúde from Madeira
Island, a region where pads are reimbursed.
RESULTS: The global prevalence of urinary incontinence
in Portugal was of 4,3%, being 2,6% in males and 5,8% in
females. Age and sex adjusted prevalence rates were of
1,9% in males while 4,4% in females. Age and sex specific
prevalence rates increase with age from 15 years onwards
in both sexes, being higher in females across all age groups.
Above 65 years of age 10% of men and 12% of women
suffer from urinary incontinence. Of these, 68,8% are
likely to suffer from chronic urinary incontinence. This is
the estimated burden of the disease in the general Portu-
guese population. Urinary incontinent chronic patients use
on average 4 pads per 24 hours, normally using 3 pads dur-
ing the day and 1 pad at night. Comparing the average pad
costs per day with using Tolterodine, the difference is re-
markable (648$00 PTE versus 334$60 PTE). The eco-
nomic impact of such use would reduce the health expendi-
ture in UI patients significantly.
CONCLUSION: The prevalence of UI in Portugal is
within the limits of what is mentioned in other community-
based studies. The average daily costs of treatment with
Tolterodine are lower when compared with pad usage.
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A PHARMACO-ECONOMIC CASE STUDY 
IN ANAESTHESIA, INCLUDING A 
RECENT RE-ANALYSIS USING
BOOTSTRAP TECHNIQUES
McNamara J, Gillis S
Biostatistics Group, PAREXEL International, Sheffield, UK
OBJECTIVES: To apply bootstrap techniques to derive
confidence intervals (CIs) for cost differences between two
anaesthetic regimes, and to compare with standard para-
metric methods for deriving CIs.
METHODS: In a cardiac surgery clinical trial, patients were
randomized to one of two anaesthetic regimes, either propo-
fol or midazolam, for the induction and maintenance of an-
esthesia, and sedation post-surgery in ICU. A cost compari-
son of these two regimes was published in 1996, with all
drug usage and ICU nursing time costs. Parametric methods
were used to construct 95% CIs for the difference between
propofol and midazolam. Untransformed parametric analy-
sis of cost data often fails because of distributional skew-
ness. Therefore, log-transformed analysis was undertaken to
overcome the skewness problem. More recently, log-trans-
formation has become a discredited strategy because health-
care decision-makers focus on total budgets—for instance,
the total annual budget available to provide surgery at a
particular centre. The only estimator directly linked to this
total cost is the arithmetic mean—therefore any analysis
based upon geometric means, arising from log-transforma-
tion, is inappropriate. Other authors have therefore recom-
mended bootstrap techniques to produce CIs for cost differ-
ences on an untransformed scale. This approach is not
invalidated by distributional skewness.
RESULTS: With 37 propofol and 33 midazolam patients,
a comparison of drug plus nursing costs showed an advan-
tage per subject for propofol of £43.23 (95% CI: £3.21
to £89.67). An untransformed two-sample t-test proved in-
appropriate, because the necessary distributional assump-
tions were not satisfied. Bootstrap CIs for the cost differ-
ence were then constructed using four different bootstrap
techniques. All bootstrap CIs showed a striking similarity
to the untransformed estimates above, demonstrating the
robustness of the t-test and conventional parametric meth-
ods, despite distributional skewness.
CONCLUSIONS: Both untransformed and bootstrap esti-
mates should be presented—hopefully, the two methods will
be in agreement and provide mutually supportive evidence.
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OBJECTIVE: To develop and validate a brief survey of mi-
graine-related quality of life issues. Unlike other instru-
ments that define the impact of acute treatment, the Qual-
ity of Life with Migraine (QOLWM) questionnaire was
designed to assess the chronic impact of migraine.
METHODS: Major issues related to living with chronic,
frequent migraine headaches were condensed into seven
topics. Each item was structured as a question about fre-
quency and a question about bothersomeness. Item scores
were the products of frequency and bothersomeness. The
total score was the sum of the seven item scores. People
with migraine who voluntarily responded to a headache
survey also completed the QOLWM and the Headache
Disability Index (HDI).
RESULTS: The QOLWM was completed in full by 994
adults (81% women) with mean total score 77.98  40.49
(range 7–175). There were no floor or ceiling effects. Inter-
nal consistency reliability (Cronbach’s alpha) of 0.93 was
excellent, with item-scale correlations of 0.59–0.83. The
eigenvalue of the single factor was 4.78, with item loadings
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of 0.68–0.88. Scores correlated significantly with frequency
of migraines in the past month and use of prophylactic
medications daily (both p  0.0001). Correlation of the
QOLWM and HDI total scores for the 728 people who
completed both questionnaires was 0.73. Item correlations
with the HDI total score were 0.47–0.67, demonstrating
external criterion validity. Additional studies are ongoing
to assess reproducibility and responsiveness.
CONCLUSIONS: These data demonstrate the psychomet-
ric properties of the QOLWM. The brief questionnaire may
be useful as a screening tool for clinicians to evaluate the im-
pact of migraine on individuals. The two-dimensional ap-
proach to patient-reported quality of life allows individuals
to weight the impact of both frequency and bothersomeness
of chronic migraines on multiple aspects of daily life.
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LONGITUDINAL ASSESSMENT OF ASTHMA 
AND WORK OUTCOMES
Erickson SR, Kirking DM
University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: Describe relationships between changes in
work outcomes (WO) and changes in asthma severity
over a one-year period.
METHODS: This longitudinal study surveyed adults en-
rolled in a managed care organization using identical
mailed surveys. 106 respondents completed both the 1997
and 1998 questionnaires and reported working outside the
home. Self-reported WO included missed work days due
to asthma and work performance (WP) from the Func-
tional Status Questionnaire, a 6-item scale using a 4-point
Likert scale, transformed to a 100 point scale. A 4-week
time reference was used. Perceived severity was determined
by asking patients their perceived severity on a 5-point
scale from very mild to very severe; evaluated severity was
based on reported symptoms matched to national guide-
lines. Respondents were grouped by change in asthma se-
verity: improvement; no change; or decline of at least one
severity category. Analysis included descriptive statistics,
paired Student’s t-test, and McNemer’s test.
RESULTS: Initially, respondent’s mean age was 44.4
(10.9) years; 72 (68.6%) were female; 76.7% had an an-
nual family income of 
$40,000; 96.2% were Caucasian;
and 76.4% had some college education or more; 42.9%
perceived their asthma severity as very mild or mild,
38.1% moderate, and 19.1% as severe or very severe.
Based on symptoms, 32.4% were classified as intermittent
mild, 28.6% mild persistent, 36.2% moderate, and 2.9%
severe asthma. WP scores changed in the expected direc-
tion based on changes in asthma severity: no change in
perceived severity (n  58) had no significant change in
WP score (91.3  13.0 versus 92.9  12.4, p  0.52); im-
provement in perceived severity (less severe, n  17) had
improved WP scores (91.8  7.9 versus 94.4  9.4, p 
0.30); and worsening of perceived severity (n  26) had a
decline in WP score (94.4  8 versus 91.3  10.9, p 
0.07). WP score trends were similar based on evaluated se-
verity. There were no significant differences in changes in
the number of respondents who reported missing work.
CONCLUSIONS: Changes in WP are related to asthma
severity. The measure of missed days work is less consis-
tently related.
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MEDICAL EVENTS AND RESOURCE 
UTILISATION IN CANCER PAIN PATIENTS 
TREATED WITH STRONG OPIOIDS: 
AN ANALYSIS OF THE UK-GPRD DATABASE
Nuyts GD1, Haazen LM1, Jones MP2
1Janssen Pharmaceutica, Beerse, Belgium; 2Jones and Just Pty 
Ltd, Sydney, Australia
OBJECTIVES: To study the incidence of medical events
and resource utilisation in patients treated for severe cancer
pain with strong opioids with the general practitioner (GP).
METHODS: We analyzed data on 2,323 cancer patients
who switched from a weak to a strong opioid. Patients
started either on TTS Fentanyl (TTS: N  270), Immedi-
ate Release Morphine (IR: N  1,909) or Sustained Re-
lease Morphine (SR: N  144). We compared the medi-
cal events during their pain treatment, the number of
patients receiving concomitant medication and the num-
ber of GP visits. A descriptive analysis was performed as
well as relative risks (RR) calculated, adjusting for rele-
vant co-variates.
RESULTS: The groups were comparable for age (avg. 68
yrs). There were more female patients in the TTS group
(61.5%) compared to 48.1% and 49.3% for IR and SR,
respectively. Median duration of cancer prior to the start
of strong opioids was 7.1 months for TTS, 6 for IR and
5.3 for SR. Mean duration of treatment: 68 days for TTS,
97 for IR and 92 for SR. No differences in concomitant
illnesses were observed except for cancer types with sig-
nificantly more GI and fewer lung cancers in the TTS
group. Compared to TTS, patients on IR had more con-
stipation (RR 1.49: 95% CI 1.14–1.94), more nausea
and vomiting (RR 1.43: 95% CI 1.09–1.88) and more
cardiac events (RR 1.95: 95% CI 1.15–3.29), while SR
patients differed from TTS only with respect to cardiac
events (RR 2.79: 95% CI 1.49–5.22). IR patients had
also a higher rate of hospitalizations (RR 1.95: 95% CI
1.14–3.31) and GP visits (RR 1.21: 95% CI 0.98–1.49).
Fewer TTS patients consumed additional pain medica-
tion, laxatives as well as antibiotics and CNS medication.
CONCLUSION: This analysis of GP derived observa-
tional data indicate that TTS Fentanyl results in a lower
consumption of medication and other health care re-
sources compared to morphine treated cancer patients.
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